CareLit · DOI-Nachweis · Diabetologie und Stoffwechsel
Efficacy and tolerability of vildagliptin in drug-naïve patients with type 2 diabetes (T2DM) and mild hyperglycemia
DOI 10.1055/s-2008-1076465
Bibliografische Angaben
Nachweis in CareLit
Autor:innenWA Scherbaum, A Schweizer, A Mari, PM Nilsson, G Lalanne, S Jauffret, J Foley
ZeitschriftDiabetologie und Stoffwechsel
Ausgabe04/2008
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Vildagliptin is a potent and selective DPP-4 inhibitor that improves glycemic control in patients with T2DM by increasing both α- and β-cell responsiveness to glucose. In earlier studies enrolling patients with T2DM and baseline A1C of 7.5 to 11%, vildagliptin 100mg daily was very well-tolerated and decreased mean A1C by 1% or more. However, despite current trends toward earlier and more aggressive intervention, pat…
Zitieren
Zitierempfehlung
WA Scherbaum, A Schweizer, A Mari, PM Nilsson, G Lalanne, S Jauffret, J Foley (2008) Efficacy and tolerability of vildagliptin in drug-naïve patients with type 2 diabetes (T2DM) and mild hyperglycemia. Diabetologie und Stoffwechsel (04). https://doi.org/10.1055/s-2008-1076465
Mit CareLit weiterarbeiten